• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care

    3/31/26 6:00:00 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care
    Get the next $BBNX alert in real time by email

    IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of Bionic Insights™, an innovative new feature within its Bionic Reports, designed to help healthcare providers (HCPs) make more informed, personalized treatment recommendations for people living with diabetes.

    As the first and only insulin pump company to deliver this level of intelligent reporting, Beta Bionics is redefining how clinicians interpret patient data. Bionic Insights goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities and system events that directly influence outcomes – giving providers unprecedented clarity into what's working and where support is needed.

    "Bionic Insights can change how clinicians interact with diabetes data," said Steven Russell, MD, PhD, Chief Medical Officer at Beta Bionics, "because it transforms complex data into clear, actionable guidance. It highlights successes and opportunities, allowing physicians to have more productive conversations with their patients and make targeted recommendations that improve outcomes. This is an important step forward in helping people achieve better glucose control."

    Turning Data into Actionable Insight

    Bionic Insights introduces a new level of intelligence within the Bionic Report by organizing information into two key categories:

    • Areas of Success – such as strong time in range, stable overnight glucose, and mostly usual meal announcements – enabling providers to reinforce positive interactions.
    • Areas of Opportunity – including frequent insulin pauses, rebound highs, prolonged hyperglycemia, or missed meal announcements – paired with educational guidance to support improvement.



    This structured approach allows clinicians to quickly identify the drivers behind glucose outcomes, reducing time spent interpreting raw data and increasing time spent on meaningful patient care decisions.

    "Bionic Insights gives both providers and patients a shared understanding of what's happening and why," added Dr. Russell. "That clarity makes it easier to have focused, productive conversations with patients about how to get the most from their iLet."

    With Bionic Insights, Beta Bionics continues its mission to simplify diabetes management and improve lives through innovation – bringing smarter, more intuitive tools to the forefront of automated insulin delivery.

    About Beta Bionics

    Headquartered in Irvine, California, Beta Bionics, Inc. is redefining what's possible in diabetes care. By listening to people living with diabetes, their families, and their care teams, the company created the iLet Bionic Pancreas – the only automated insulin delivery system with a closed loop algorithm that adapts to each person in order to determine and deliver every insulin dose, reducing the daily burden on users. With this unique, innovative approach, Beta Bionics is focused on bringing greater ease, confidence, and freedom to people managing diabetes every day. To learn more, visit www.betabionics.com.

    Investor Relations Contact:

    [email protected]

    Media and Public Relations Contact:

    [email protected]



    Primary Logo

    Get the next $BBNX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BBNX

    DatePrice TargetRatingAnalyst
    2/9/2026$24.00Buy
    UBS
    1/27/2026$17.00Hold
    TD Cowen
    1/9/2026Buy → Neutral
    BofA Securities
    10/21/2025$26.00Buy
    Stifel
    10/1/2025$26.00Neutral → Buy
    Goldman
    6/16/2025$26.00Buy
    Truist
    6/12/2025$30.00Buy
    Lake Street
    5/30/2025$16.00Neutral
    Goldman
    More analyst ratings

    $BBNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Medical Officer Russell Steven Jon sold $30,069 worth of shares (1,025 units at $29.34), decreasing direct ownership by 0.57% to 178,071 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    3/16/26 7:55:04 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Chief Commercial Officer Hopman Mark sold $88,304 worth of shares (2,917 units at $30.27), decreasing direct ownership by 2% to 136,216 units (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    3/16/26 7:55:07 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 4 filed by Chief Commercial Officer Hopman Mark

    4/A - Beta Bionics, Inc. (0001674632) (Issuer)

    3/13/26 4:15:17 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care

    IRVINE, Calif., March 31, 2026 (GLOBE NEWSWIRE) -- Beta Bionics today announced the launch of Bionic Insights™, an innovative new feature within its Bionic Reports, designed to help healthcare providers (HCPs) make more informed, personalized treatment recommendations for people living with diabetes. As the first and only insulin pump company to deliver this level of intelligent reporting, Beta Bionics is redefining how clinicians interpret patient data. Bionic Insights goes beyond traditional glucose reporting by surfacing clinically relevant indicators, patient activities and system events that directly influence outcomes – giving providers unprecedented clarity into what's working and

    3/31/26 6:00:00 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026

    IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's first quarter 2026 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To

    3/30/26 4:11:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Present at the TD Cowen 46th Annual Health Care Conference

    IRVINE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at TD Cowen's 46th Annual Health Care Conference on Wednesday, March 4, 2026 at 10:30 am Eastern Time (7:30 am Pacific Time). A live audio webcast of the presentation will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay following the event. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, a

    2/19/26 4:05:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Product Officer Mensinger Mike bought $566,950 worth of shares (33,350 units at $17.00), converted options into 15,107 shares, exercised 10,575 in-the-money shares at a strike of $0.02 and sold $221 worth of shares (13 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 8:30:15 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Large owner Wellington Hadley Harbor Aggregator Iv, L.P. converted options into 2,901,599 shares and bought $17,000,000 worth of shares (1,000,000 units at $17.00) (SEC Form 4)

    4 - Beta Bionics, Inc. (0001674632) (Issuer)

    2/3/25 4:49:52 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on Beta Bionics with a new price target

    UBS initiated coverage of Beta Bionics with a rating of Buy and set a new price target of $24.00

    2/9/26 7:00:55 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    TD Cowen initiated coverage on Beta Bionics with a new price target

    TD Cowen initiated coverage of Beta Bionics with a rating of Hold and set a new price target of $17.00

    1/27/26 8:43:35 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics downgraded by BofA Securities

    BofA Securities downgraded Beta Bionics from Buy to Neutral

    1/9/26 8:48:15 AM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Beta Bionics Inc.

    SCHEDULE 13G/A - Beta Bionics, Inc. (0001674632) (Subject)

    3/26/26 4:08:21 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    SEC Form 144 filed by Beta Bionics Inc.

    144 - Beta Bionics, Inc. (0001674632) (Subject)

    3/4/26 4:58:14 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    SEC Form S-3ASR filed by Beta Bionics Inc.

    S-3ASR - Beta Bionics, Inc. (0001674632) (Filer)

    2/24/26 5:03:29 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    $BBNX
    Leadership Updates

    Live Leadership Updates

    View All

    InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

    MIAMI, Sept. 17, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (NASDAQ:NSPR) ("InspireMD" or the "Company"), developer of the CGuard® Prime carotid stent system for the prevention of stroke, today announced the appointment of Dan Dearen to its Board of Directors. Mr. Dearen brings nearly 40 years of leadership experience in the medical device and life sciences sectors, with a proven track record of guiding MedTech companies through critical financial milestones and delivering shareholder value through execution. "We are pleased to welcome Dan to InspireMD's Board of Directors," said Marvin Slosman, Chief Executive Officer of InspireMD. "He brings extensive experience, financial expertise, and

    9/17/25 8:00:00 AM ET
    $BBNX
    $NSPR
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Board Appointment of Gerard Michel

    IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (NASDAQ:DCTH), a commercial-stage interventional oncology company. "We are excited to welcome Gerard to the Beta Bionics Board," said Sean Saint, President and Chief Executive Officer of Beta Bionics. "Gerard is a highly regarded leader in the pharmaceutical and medical technology industries, and brings deep experience in driving innovation a

    3/27/25 4:45:06 PM ET
    $BBNX
    $DCTH
    Medical/Dental Instruments
    Health Care

    $BBNX
    Financials

    Live finance-specific insights

    View All

    Beta Bionics to Announce First Quarter 2026 Financial Results on April 21, 2026

    IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its first quarter 2026 financial results after the financial markets close on Tuesday, April 21, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's first quarter 2026 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archived there for future replay. To

    3/30/26 4:11:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics Announces Fourth Quarter and Full Year 2025 Financial Results and Introduces Annual Guidance for Full Year 2026

    IRVINE, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today reported its financial results for the quarter and year ended December 31, 2025 and introduced its annual guidance for the year ending December 31, 2026. Fourth Quarter 2025 Financial Highlights & Key Metrics Net sales of $32.1 million, up 57% compared to $20.4 million in the fourth quarter of 2024. Durable Medical Equipment (DME) channel net sales of $22.3 million, up 24% compared to $18.0 million in the fourth quarter of 2024.Pharmacy Benefit Plan (PBP) channel net sales of $9.8 million, up 295% compared to $2.5 mill

    2/17/26 4:05:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care

    Beta Bionics to Announce Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026

    IRVINE, Calif., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (NASDAQ:BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2025 financial results after the financial markets close on Tuesday, February 17, 2026. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company's fourth quarter and full year 2025 performance. The link to the webcast will be available on the Company's website in the "Investors—Events & Presentations" section at https://investors.betabionics.com, and will be archi

    1/15/26 4:03:00 PM ET
    $BBNX
    Medical/Dental Instruments
    Health Care